Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garadacimab in PICC-associated Thrombosis
NCT04281524Phase 2Withdrawn
- Sponsor
- CSL Limited
- Start
- Mar 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of garadacimab in PICC-associated thrombosis (5 arms), sponsored by CSL Limited. Primary endpoints: Number of subjects with PICC-associated thrombosis at 29 days and Percent of subjects with PICC-associated thrombosis at 29 days. Planned start Mar 2020; status: withdrawn.
02
Drugs
garadacimab
03
Conditions
PICC-associated thrombosis
Beyond the preview
Go deeper on NCT04281524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04281524.